Skip to Main Content

Paper Details

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Haematologica
39
2019
Author NameAffiliation
Jamshid S KhorashadImperial College
Jamshid S KhorashadImperial College Healthcare NHS Trust
  • 1 - 2

Datasets

Release 1.2